Tag: vaccine

  • Shares of Pfizer Just Got a Substantial Boost

    Shares of Pfizer Just Got a Substantial Boost

    There goes Pfizer (PFE). The stock is popping on news it’s buying ReViral – a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV) for $525 million. “Currently, treatment options for RSV are extremely limited and focus primarily on supportive care,” said Annaliesa Anderson,…

  • This is Why Pfizer Just Popped, As We Expected

    This is Why Pfizer Just Popped, As We Expected

    Pfizer is pushing to higher highs. In fact, as we noted on November 2, “After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term.  All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses.  The stock could…

  • This is Why Shares of Pfizer Could Race Higher

    This is Why Shares of Pfizer Could Race Higher

    Pfizer is pushing to higher highs. After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term.  All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses.  The stock could push even higher on a US CDC vote.…

  • Johnson & Johnson (JNJ) May Be Ready to Rebound

    Johnson & Johnson (JNJ) May Be Ready to Rebound

    Keep an eye on Johnson & Johnson (JNJ). After pulling back from a high of $173.65, it caught support at $161.99.  From here, the stock could again test prior highs if the US FDA grants emergency authorization for its vaccine. With a 66% effective rate in protecting against the virus, JNJ applied for emergency use.…

  • The Top 3 Vaccine Trades that Should be in All Portfolios

    The Top 3 Vaccine Trades that Should be in All Portfolios

    Moderna (MRNA) has been incredibly explosive for us. The first time we highlighted opportunity, the stock traded at $72 on Oct. 20.  At the moment, it’s up to $171.92 in pre-market, and we still believe it could rally to $200. For one, “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19…

  • COVID-19 Vaccine: The Top Two Stocks to Consider Immediately

    COVID-19 Vaccine: The Top Two Stocks to Consider Immediately

    The pandemic is only getting worse. At the moment, there are nearly 40 million global cases, with 1.1 million deaths.  In the U.S., the count is up to 8.14 million.  India is up to nearly 75. Million.  Brazil is up to 5.2 million.  Russia is nearing 1.4 million.  Colombia is up to 952,373. In Paris,…

  • The Top Two Vaccine Stocks to Avoid

    The Top Two Vaccine Stocks to Avoid

    There’s no such thing as a perfect trial. Fortunately, there are safeguards in place to stop trials in the event of a mishap.  We’ve seen two just this week, which could put a good deal of pressure on their stocks. Hopefully, the events won’t prevent these companies from moving forward for long. Shares of Eli…

  • This Pandemic Stock Has Just Begun to Push Higher

    This Pandemic Stock Has Just Begun to Push Higher

    Keep an eye on Altimmmune Inc. (ALT). The stock is pushing higher thanks to more positive data on its COVID candidate. The company just published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID, adding the candidate “stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract.” “AdCOVID is designed to offer significant…

  • The Top 3 COVID-19 Treatment Stocks to Watch

    The Top 3 COVID-19 Treatment Stocks to Watch

    With the coronavirus showing no signs of slowing, the world is in desperate need for a treatment — and fast.  Thankfully, we may be nearing potential solutions, which could drive these three stocks even higher. One, shares of OPKO Health (OPK) are picking up a good deal of momentum, as markets wait for news on…